“
TL;DR
This narrative review describes the broad clinical spectrum, management challenges, and evolving therapeutic options for alcohol-associated liver disease in human patients.
Drugs · 3 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review describes the broad clinical spectrum, management challenges, and evolving therapeutic options for alcohol-associated liver disease in human patients.
This narrative review synthesizes current knowledge on alcohol-associated liver disease (ALD), a major cause of liver disease globally. It highlights that ALD spans a spectrum from asymptomatic steatosis to decompensated cirrhosis and that many cases remain undiagnosed. The review advocates for systematic screening and a multidisciplinary management approach that addresses comorbid conditions. It discusses a range of existing therapeutic interventions aimed at supporting alcohol cessation and maintaining remission, with abstinence as the ultimate goal. The text notes that these treatments are often underutilized and their availability varies geographically. Recent innovations, such as the clinical use of alcohol consumption biomarkers and the expansion of liver transplantation eligibility to include severe alcohol-associated hepatitis, are also explored.